Skip to main content
Journal cover image

Renal medullary carcinoma: A national analysis of 159 patients.

Publication ,  Journal Article
Ezekian, B; Englum, B; Gilmore, BF; Nag, UP; Kim, J; Leraas, HJ; Routh, JC; Rice, HE; Tracy, ET
Published in: Pediatr Blood Cancer
November 2017

BACKGROUND: Renal medullary carcinoma (RMC) is an aggressive malignancy seen predominantly in young males with sickle cell trait. RMC is poorly understood, with fewer than 220 cases described in the medical literature to date. We used a large national registry to define the typical presentation, treatments, and outcomes of this rare tumor. METHODS: The National Cancer Database was queried for patients under 40 years of age diagnosed with RMC from 1998 to 2011. An analysis of patient and tumor characteristics, treatment details, and overall survival (OS) was undertaken, and factors associated with mortality were identified using multivariable regression analysis. RESULTS: In total, 159 patients with RMC were identified, of whom a majority were male (71%), African American (87%), and had metastatic disease (71%). Median tumor size was 6 cm and median survival was 7.7 months. Most patients underwent surgery (60%) and chemotherapy (65%). Few patients received radiation (12%). Patients with metastatic disease had a significantly worse median survival (4.7 vs. 17.8 months, P < 0.001) and were less likely to receive surgery (42% vs. 91%, P < 0.001). Age and tumor size did not appear to impact OS. CONCLUSION: In the largest cohort to date of patients with RMC, we found a dismal median survival of less than 8 months. Age and tumor size were not associated with OS. Metastatic disease at presentation was the main negative prognostic indicator in RMC and was present in a majority of patients at the time of diagnosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

November 2017

Volume

64

Issue

11

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Rate
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Kidney Neoplasms
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ezekian, B., Englum, B., Gilmore, B. F., Nag, U. P., Kim, J., Leraas, H. J., … Tracy, E. T. (2017). Renal medullary carcinoma: A national analysis of 159 patients. Pediatr Blood Cancer, 64(11). https://doi.org/10.1002/pbc.26609
Ezekian, Brian, Brian Englum, Brian F. Gilmore, Uttara P. Nag, Jina Kim, Harold J. Leraas, Jonathan C. Routh, Henry E. Rice, and Elisabeth T. Tracy. “Renal medullary carcinoma: A national analysis of 159 patients.Pediatr Blood Cancer 64, no. 11 (November 2017). https://doi.org/10.1002/pbc.26609.
Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ, et al. Renal medullary carcinoma: A national analysis of 159 patients. Pediatr Blood Cancer. 2017 Nov;64(11).
Ezekian, Brian, et al. “Renal medullary carcinoma: A national analysis of 159 patients.Pediatr Blood Cancer, vol. 64, no. 11, Nov. 2017. Pubmed, doi:10.1002/pbc.26609.
Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ, Routh JC, Rice HE, Tracy ET. Renal medullary carcinoma: A national analysis of 159 patients. Pediatr Blood Cancer. 2017 Nov;64(11).
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

November 2017

Volume

64

Issue

11

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Rate
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Kidney Neoplasms
  • Humans
  • Follow-Up Studies
  • Female